Array BioPharma Inc. announced positive results from the interim analysis of the Phase 3 BEACON CRC trial evaluating the combination of BRAFTOVI®, a BRAF inhibitor, MEKTOVI®, a MEK inhibitor, and ERBITUX®, an anti-EGFR antibody, in patients with BRAFV600E-mutant metastatic colorectal cancer, following one or two prior lines of therapy.
May 21, 2019
· 20 min read